| Name | 4-(hexadecylamino)benzoic acid |
|---|---|
| Synonyms |
4-(Hexadecylamino)benzoic acid
Peroxisome Proliferator,Cetaben Benzoic acid, 4-(hexadecylamino)- Cetaben |
| Description | Cetaben, an exceptional type of peroxisome proliferator, is a peroxisome proliferator-activated receptor α (PPARα)-independent peroxisome proliferator. Cetaben is a non-fibrate hypolipidemic drug and potently reduces the concentration of cholesterol and triglycerides[1][2]. |
|---|---|
| Related Catalog | |
| In Vitro | Cetaben (10 µM; 24 hours) induces severe micromorphological and ultrastructural changes in HepG2 and MH1C1 cells. After treatment with 100 µM cetaben, cells contained several Golgi regions, most of them disintegrated into vesicles[2]. Cetaben-treated (10 µM; 24 hours) cells were characterized by a striking heterogeneity of the peroxisomal population with the occurrence of dumbbell-shaped and cup-shaped peroxisomal profiles in MH1C1cells[2]. |
| In Vivo | Cetaben reveales a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body over 10 days, but the maximal effect is observed at 250 mg/kg[1]. Animal Model: Male Wistar rats[1] Dosage: 10,25,50,100,250 and 500 mg/kg Administration: Gavage; 10 day Result: Revealed a significant rise in the activities of peroxisomal enzymes in both the liver and kidney at doses of 50-100 mg/kg body over 10 days, but the maximal effect was observed at 250 mg/kg. |
| References |
| Density | 1.0±0.1 g/cm3 |
|---|---|
| Boiling Point | 503.4±33.0 °C at 760 mmHg |
| Molecular Formula | C23H39NO2 |
| Molecular Weight | 361.561 |
| Flash Point | 258.3±25.4 °C |
| Exact Mass | 361.298065 |
| PSA | 49.33000 |
| LogP | 9.68 |
| Vapour Pressure | 0.0±1.4 mmHg at 25°C |
| Index of Refraction | 1.521 |
| Storage condition | -20°C |
CHEMICAL IDENTIFICATION
HEALTH HAZARD DATAACUTE TOXICITY DATA
|
| HS Code | 2922499990 |
|---|
|
~92%
55986-43-1 |
| Literature: Albright; DeVries; Largis; Miner; Reich; Schaffer; Shepherd; Upeslacis Journal of Medicinal Chemistry, 1983 , vol. 26, # 10 p. 1378 - 1393 |
|
~%
55986-43-1 |
| Literature: LEK tovarna farmacevtskih in kemicnih izdelkov, n.sol.o. Patent: US4304929 A1, 1981 ; |
|
~%
55986-43-1 |
| Literature: Albright; DeVries; Largis; Miner; Reich; Schaffer; Shepherd; Upeslacis Journal of Medicinal Chemistry, 1983 , vol. 26, # 10 p. 1378 - 1393 |
|
~%
55986-43-1 |
| Literature: Albright; DeVries; Largis; Miner; Reich; Schaffer; Shepherd; Upeslacis Journal of Medicinal Chemistry, 1983 , vol. 26, # 10 p. 1378 - 1393 |
|
~%
55986-43-1 |
| Literature: Albright; DeVries; Largis; Miner; Reich; Schaffer; Shepherd; Upeslacis Journal of Medicinal Chemistry, 1983 , vol. 26, # 10 p. 1378 - 1393 |
|
~%
55986-43-1 |
| Literature: Albright; DeVries; Largis; Miner; Reich; Schaffer; Shepherd; Upeslacis Journal of Medicinal Chemistry, 1983 , vol. 26, # 10 p. 1378 - 1393 |
| Precursor 6 | |
|---|---|
| DownStream 0 | |
| HS Code | 2922499990 |
|---|---|
| Summary | HS:2922499990 other amino-acids, other than those containing more than one kind of oxygen function, and their esters; salts thereof VAT:17.0% Tax rebate rate:9.0% Supervision conditions:AB(certificate of inspection for goods inward,certificate of inspection for goods outward) MFN tariff:6.5% General tariff:30.0% |